Patent protection rules that curb competition for medicines in markets outside the European Union should be changed, the European commission has proposed. Photograph: Julien Behal/PA Wire

Patent protection rules that curb competition for medicines in markets outside the European Union should be changed, the European commission has propo(...)

Bernard Mallee is charged with “helping the biopharmaceutical industry to tell an impactful story about the value it creates for patients, society and the economy, with innovation at the core”

The group representing the major drug development companies in Ireland has beefed up its communications team. The Irish Pharmaceutical Healthcare Ass(...)

Photograph: iStock

Irish patients are being denied access to nine drugs that are widely available across Europe, largely on cost grounds. The drugs – most of them cance(...)

The nine drugs include Erivedge for basal cell carcinoma, Brintellix for depression and Entresto for heart failure. File photograph: Getty Images

Nine new high-tech medicines are to be made available to patients within months following the resolution of a funding dispute between the Health Servi(...)

Nine medications are currently stalled at the desk of the Minister for Health even though they have been approved for use by the Health Service Executive

Drug companies are increasingly frustrated at the Government’s failure to offer any assurances on clearing a logjam of new medicines that are waiting (...)

Thousands of patients are being deprived of access to new medicines because the Health Service Executive has no money left to fund them this year. So(...)

Graffiti on Charlemont Place at the side of the Grand Canal in Dublin. The agreement between the HSE and Vertex Pharmaceuticals has been warmly welcomed. Photograph:  Nick Bradshaw

Politicians and advocacy groups have welcomed the deal between the State and the manufacturers of drugs used to treat people with cystic fibrosis (CF)(...)

Arrival of biosimilars is expected to deliver savings of more than €100m over the four-year life of the agreement

The Irish healthcare system must do more to encourage competition by generic and biosimilar drugs if it is to cut Ireland’s drug bill and provide fund(...)

The prices of almost 1,000 commonly-used medicines have dropped since last August

A new price agreement between the State and drugs manufacturers is on course to achieve savings of €140 million in its first year, according to the in(...)

Where a generic medicine is a cheaper identical “copy” of a branded traditional small molecule drug, biosimilar are “me-too” versions of modern, large molecule complex biologic medicines

Switching from a branded biologic drug to a cheaper “biosimilar” makes no meaningful difference to patients suffering from a series of chronic inflamm(...)

  • « First
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next
  • Last »